3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Whereas Viking's shares are up by 610% over the last three years, Altimmune's are down by 54%. However, there's more than one argument for why Altimmune's next act could look a lot more like Viking's trajectory. So let's examine three reasons it might be the next weight loss biotech to soar. 1. It's eyeing the same astronomically large market If you've been keeping up with the biopharmaceutical sector lately, you know that weight loss drugs like Eli Lilly 's Zepbound and Novo Nordisk 's Wegovy are all the rage. Per the World Health Organization (WHO), by 2025, nearly 1 billion people globally will fit the criteria for obesity. The allure of the profits awaiting in that market is driving investors to bid up Viking's shares -- and the same could now be the case with Altimmune, which also has an obesity medicine in development. Estimates of the dollar value of the market vary widely, but the consensus is that to merely call it "big" is an understatement. Per some calculations by
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- C2N Diagnostics Says FDA's Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer's Disease Pathology [Yahoo! Finance]Yahoo! Finance
- South Florida expert on what you need to know about new Alzheimer's drug [CBS News]CBS News
- FDA approves new drug for Alzheimer's disease: ‘Meaningful results' [FOX News]FOX News
- FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S. [MSNBC.com]MSNBC.com
- ALZHEIMER'S DRUG DISCOVERY FOUNDATION (ADDF) STATEMENT ON FDA'S TRADITIONAL APPROVAL OF KISUNLA (DONANEMAB) [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 7/2/24 - Form 4
- 7/1/24 - Form 4
- 6/28/24 - Form 144
- LLY's page on the SEC website